Comparator supply for NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Sponsor: AstraZeneca (INDUSTRY). Phase: PHASE3. Status: Recruiting. Countries: United States, Australia, Brazil, Canada, China, Denmark, France, Germany, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Korea, Spain, Taiwan, United Kingdom. Last update posted 2026-10-21.
Registry record: https://clinicaltrials.gov/study/NCT07735637.
Canadian-labelled cyclophosphamide
12 marketed Canadian product(s) from 4 manufacturer(s) contain cyclophosphamide. Available strengths: 1000 MG, 200 MG, 2000 MG, 25 MG, 50 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled fludarabine
3 marketed Canadian product(s) from 3 manufacturer(s) contain fludarabine phosphate. Available strengths: 10 MG, 25 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled lenalidomide
42 marketed Canadian product(s) from 7 manufacturer(s) contain lenalidomide. Available strengths: 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled melphalan
1 marketed Canadian product(s) from 1 manufacturer(s) contain melphalan. Available strengths: 2 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled cyclophosphamide as a trial comparator?
Yes. We source Canadian-marketed cyclophosphamide under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT07735637.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1 (431) 588-9055.